远大医药预计2025年净利润减少至12亿港元至12.5亿港元

财中社03-22

3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Kita1a
03-23
Kita1a
这不完犊子了
- Kita1a回复生煎鸭子:
  硬挺，我争取不哭就行[开心]
- 生煎鸭子回复Kita1a:
  曙光咋现，稳住
- Kita1a:
  疼😭
- 生煎鸭子:
  可安好？ [得意]

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621771915?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-22 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621771915","market":"hk","top_or_hot":-1,"title":"远大医药预计2025年净利润减少至12亿港元至12.5亿港元","media":"财中社","content":"<div>\n<p>3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603223679731313.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>远大医药预计2025年净利润减少至12亿港元至12.5亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n远大医药预计2025年净利润减少至12亿港元至12.5亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 16:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603223679731313.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603223679731313.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603223679731313.html","article_id":"2621771915","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621771915","pubTimestamp":1774166640,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"00512":"远大医药"},"translate_title":"Yuanda Pharma expects net profit to decrease to HK$1.2 billion to HK$1.25 billion in 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":1.5},"content_text":"3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分产品受药品集中采购降价影响，相关产品毛利同比减少逾6亿港元。　　此外，公告提到，本集团在推广核心创新壁垒产品方面增加了逾5亿港元的营销推广费用。尽管面临集中采购降价的阶段性影响，但集采降价的影响已被充分消化，公司的年度收入和毛利均较去年有所上升。预计截至2025年12月31日止年度的收益在120亿港元至125亿港元之间，较2024同期的116.4亿港元有所增长。核心经营质量展现出强劲韧性，创新壁垒产品收入占比首次提升至约50%。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":545664273019672,"gmtCreate":1774228175369,"gmtModify":1774229152219,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","vip":1,"crmLevel":6,"crmLevelSwitch":1,"wearingBadges":[],"authorIdStr":"4192178964309222","idStr":"4192178964309222"},"htmlText":"这不完犊子了","listText":"这不完犊子了","text":"这不完犊子了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/545664273019672","repostId":2621771915,"repostType":2,"repost":{"id":"2621771915","kind":"news","pubTimestamp":1774166640,"share":"https://www.laohu8.com/m/news/2621771915?lang=zh_CN&edition=full","pubTime":"2026-03-22 16:04","market":"hk","language":"zh","title":"远大医药预计2025年净利润减少至12亿港元至12.5亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621771915","media":"财中社","summary":"3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.00512&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　3月20日，<span><a href=\"https://laohu8.com/S/00512\">远大医药</a></span>（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分产品受药品集中采购降价影响，相关产品毛利同比减少逾6亿港元。</p><p>　　此外，公告提到，本集团在推广核心创新壁垒产品方面增加了逾5亿港元的营销推广费用。尽管面临集中采购降价的阶段性影响，但集采降价的影响已被充分消化，公司的年度收入和毛利均较去年有所上升。预计截至2025年12月31日止年度的收益在120亿港元至125亿港元之间，较2024同期的116.4亿港元有所增长。核心经营质量展现出强劲韧性，创新壁垒产品收入占比首次提升至约50%。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>远大医药预计2025年净利润减少至12亿港元至12.5亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n远大医药预计2025年净利润减少至12亿港元至12.5亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 16:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603223679731313.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603223679731313.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00512":"远大医药"},"source_url":"http://finance.eastmoney.com/a/202603223679731313.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2621771915","content_text":"3月20日，远大医药（00512）发布公告，预期截至2025年12月31日止年度的本公司拥有人应占期内溢利在12亿港元至12.5亿港元之间，相比于2024年同期的24.7亿港元，预计将大幅减少。同时，预计截至2025年同期的本公司拥有人应占经调整的经营性纯利在14.5亿港元至15亿港元之间，而2024年同期为17.6亿港元。公告指出，溢利减少的主要原因包括股权投资的公允价值损失约3.3亿港元及部分产品受药品集中采购降价影响，相关产品毛利同比减少逾6亿港元。　　此外，公告提到，本集团在推广核心创新壁垒产品方面增加了逾5亿港元的营销推广费用。尽管面临集中采购降价的阶段性影响，但集采降价的影响已被充分消化，公司的年度收入和毛利均较去年有所上升。预计截至2025年12月31日止年度的收益在120亿港元至125亿港元之间，较2024同期的116.4亿港元有所增长。核心经营质量展现出强劲韧性，创新壁垒产品收入占比首次提升至约50%。（文章来源：财中社）","news_type":1,"symbols_score_info":{"00512":1.5}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":545864882014144,"gmtCreate":1774277223202,"gmtModify":1774277347466,"authorId":4192178964309222,"author":{"id":4192178964309222,"idStr":"4192178964309222","authorId":4192178964309222,"name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.25","exceedPercentage":"93.98%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":3545732952498700,"repliedAuthor":{"id":3545732952498700,"idStr":"3545732952498700","authorId":3545732952498700,"name":"生煎鸭子","avatar":"https://static.tigerbbs.com/29ebbc3cb0e82073e4fd5a149e98e7a9","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.04","exceedPercentage":"93.72%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}]},"objectId":545664273019672,"type":1,"supId":545842058076208,"prevId":545864999732144,"content":"硬挺，我争取不哭就行[开心]","text":"硬挺，我争取不哭就行[开心]","html":"硬挺，我争取不哭就行[开心]"},{"id":545864999732144,"gmtCreate":1774277182804,"gmtModify":1774277187265,"authorId":3545732952498700,"author":{"id":3545732952498700,"idStr":"3545732952498700","authorId":3545732952498700,"name":"生煎鸭子","avatar":"https://static.tigerbbs.com/29ebbc3cb0e82073e4fd5a149e98e7a9","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.04","exceedPercentage":"93.72%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}]},"repliedAuthorId":4192178964309222,"repliedAuthor":{"id":4192178964309222,"idStr":"4192178964309222","authorId":4192178964309222,"name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.25","exceedPercentage":"93.98%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[]},"objectId":545664273019672,"type":1,"supId":545842058076208,"prevId":545864032968832,"content":"曙光咋现，稳住","text":"曙光咋现，稳住","html":"曙光咋现，稳住"},{"id":545864032968832,"gmtCreate":1774277017534,"gmtModify":1774277022123,"authorId":4192178964309222,"author":{"id":4192178964309222,"idStr":"4192178964309222","authorId":4192178964309222,"name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.25","exceedPercentage":"93.98%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":545664273019672,"type":1,"supId":545842058076208,"prevId":0,"content":"疼😭","text":"疼😭","html":"疼😭"},{"id":545842058076208,"gmtCreate":1774272296648,"gmtModify":1774272301109,"authorId":3545732952498700,"author":{"id":3545732952498700,"idStr":"3545732952498700","authorId":3545732952498700,"name":"生煎鸭子","avatar":"https://static.tigerbbs.com/29ebbc3cb0e82073e4fd5a149e98e7a9","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.04","exceedPercentage":"93.72%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"wearingSort":0},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}]},"repliedAuthorId":0,"objectId":545664273019672,"type":1,"supId":0,"prevId":0,"content":"可安好？ [得意]","text":"可安好？ [得意]","html":"可安好？ [得意]"}],"langContent":"CN"}],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621771915","isCrawlerRequest":true}